WATER II (80-150 mL) procedural outcomes.

Area of Science:

• Urology
• Minimally Invasive Surgery
• Medical Devices

Background:

• Benign prostatic hyperplasia (BPH) significantly impacts quality of life in men.
• Large prostate volumes (80-150 mL) present unique challenges for effective treatment.
• Current treatment options may have limitations in efficacy or safety for large prostates.

Purpose of the Study:

• To evaluate the early safety and feasibility of aquablation therapy.
• To assess aquablation in men with large-volume benign prostatic hyperplasia (BPH).
• To present data from the multicentre prospective WATER II study.

Main Methods:

• Prospective international clinical trial (WATER II) involving 101 men with BPH (80-150 mL prostate volume).
• Aquablation procedure performed with standardized postoperative management.
• Adverse events monitored for 1 month and adjudicated by an independent committee.

Main Results:

• Mean prostate volume was 107 mL; mean operating time was 37 minutes.
• Adequate adenoma resection achieved in a single session, with a mean of 1.8 treatment passes.
• 1.6-day mean hospital stay; 29.7% Clavien-Dindo grade ≥2 event rate at 1 month, including 9.9% bleeding complications.

Conclusions:

• Aquablation demonstrates feasibility and safety for treating men with large prostates (80-150 mL).
• Early data support aquablation as a viable option for large-volume BPH.
• Longer-term efficacy data are forthcoming.